- Home
- SNPX vs HOTH Comparison
SNPX vs HOTH Comparison
Compare SNPX & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNPX
- HOTH
- Stock Information
- Founded
- SNPX 2012
- HOTH 2017
- Country
- SNPX United States
- HOTH United States
- Employees
- SNPX N/A
- HOTH N/A
- Industry
- SNPX Medicinal Chemicals and Botanical Products
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- SNPX Health Care
- HOTH Health Care
- Exchange
- SNPX Nasdaq
- HOTH Nasdaq
- Market Cap
- SNPX 3.8M
- HOTH 7.6M
- IPO Year
- SNPX N/A
- HOTH 2019
- Fundamental
- Price
- SNPX $3.01
- HOTH $1.00
- Analyst Decision
- SNPX Strong Buy
- HOTH Strong Buy
- Analyst Count
- SNPX 1
- HOTH 4
- Target Price
- SNPX $14.00
- HOTH $5.88
- AVG Volume (30 Days)
- SNPX 39.8K
- HOTH 9.0M
- Earning Date
- SNPX 08-14-2024
- HOTH 09-17-2024
- Dividend Yield
- SNPX N/A
- HOTH N/A
- EPS Growth
- SNPX N/A
- HOTH N/A
- EPS
- SNPX N/A
- HOTH N/A
- Revenue
- SNPX N/A
- HOTH N/A
- Revenue This Year
- SNPX N/A
- HOTH N/A
- Revenue Next Year
- SNPX N/A
- HOTH N/A
- P/E Ratio
- SNPX N/A
- HOTH N/A
- Revenue Growth
- SNPX N/A
- HOTH N/A
- 52 Week Low
- SNPX $2.72
- HOTH $0.58
- 52 Week High
- SNPX $11.48
- HOTH $1.98
- Technical
- Relative Strength Index (RSI)
- SNPX 40.82
- HOTH 59.87
- Support Level
- SNPX $2.72
- HOTH $1.02
- Resistance Level
- SNPX $3.67
- HOTH $1.25
- Average True Range (ATR)
- SNPX 0.28
- HOTH 0.12
- MACD
- SNPX -0.04
- HOTH 0.03
- Stochastic Oscillator
- SNPX 33.58
- HOTH 49.70
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.